New drug combo targets Hard-to-Treat myeloma
NCT ID NCT03091257
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This study tests two targeted drugs, dabrafenib and trametinib, in 30 people with multiple myeloma that has returned or not responded to treatment. The goal is to see if these drugs can shrink the cancer. Participants must have measurable signs of myeloma. The study is in an early phase and focuses on safety and response rate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.